ECSP15038626A - A61k 30/395 - Google Patents

A61k 30/395

Info

Publication number
ECSP15038626A
ECSP15038626A ECIEPI201538626A ECPI201538626A ECSP15038626A EC SP15038626 A ECSP15038626 A EC SP15038626A EC IEPI201538626 A ECIEPI201538626 A EC IEPI201538626A EC PI201538626 A ECPI201538626 A EC PI201538626A EC SP15038626 A ECSP15038626 A EC SP15038626A
Authority
EC
Ecuador
Prior art keywords
antibody
useful
treatment
lupus
psoriasis
Prior art date
Application number
ECIEPI201538626A
Other languages
English (en)
Inventor
Daniel Scott Girard
Stuart Willis Bright
Kristine Kay Kikly
Catherine Brautigam Beidler
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ECSP15038626A publication Critical patent/ECSP15038626A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se refiere a un anticuerpo que se une a la subunidad p19 de IL-23 humana y se caracteriza por tener alta afinidad, propiedades selectivas y neutralizantes. El anticuerpo es útil en el tratamiento o prevención de una condición autoinmune o inflamatoria se selecciona a partir del grupo que consiste de esclerosis múltiple, artritis reumatoide, psoriasis, enfermedades inflamatorias del intestino, espondilitis anquilosante, enfermedad de injerto contra hospedero, lupus y síndrome metabólico. El anticuerpo es también útil en el tratamiento de cáncer.
ECIEPI201538626A 2013-03-08 2015-09-08 A61k 30/395 ECSP15038626A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361774732P 2013-03-08 2013-03-08

Publications (1)

Publication Number Publication Date
ECSP15038626A true ECSP15038626A (es) 2015-11-30

Family

ID=51488096

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI201538626A ECSP15038626A (es) 2013-03-08 2015-09-08 A61k 30/395

Country Status (40)

Country Link
US (3) US9023358B2 (es)
EP (3) EP2964258B1 (es)
JP (1) JP6096938B2 (es)
KR (2) KR20170103037A (es)
CN (1) CN105307681B (es)
AP (1) AP2015008708A0 (es)
AR (1) AR094877A1 (es)
BR (1) BR112015019611B1 (es)
CA (1) CA2901462C (es)
CL (1) CL2015002388A1 (es)
CY (2) CY1123589T1 (es)
DK (1) DK2964258T3 (es)
EA (1) EA031524B1 (es)
EC (1) ECSP15038626A (es)
ES (1) ES2822662T3 (es)
FI (1) FIC20230030I1 (es)
FR (1) FR23C1036I2 (es)
HK (1) HK1212252A1 (es)
HR (1) HRP20201633T1 (es)
HU (2) HUE051357T2 (es)
IL (2) IL240731B (es)
JO (1) JOP20140049B1 (es)
LT (1) LT2964258T (es)
MA (1) MA38382A1 (es)
MX (1) MX370396B (es)
MY (1) MY171226A (es)
NL (1) NL301247I2 (es)
NO (1) NO2023037I1 (es)
PE (1) PE20151529A1 (es)
PH (1) PH12015501994A1 (es)
PL (1) PL2964258T3 (es)
PT (1) PT2964258T (es)
RS (1) RS60928B1 (es)
SG (1) SG11201507176VA (es)
SI (1) SI2964258T1 (es)
TN (1) TN2015000348A1 (es)
TW (1) TWI636063B (es)
UA (1) UA123198C2 (es)
WO (1) WO2014137962A1 (es)
ZA (1) ZA201505285B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR102417A1 (es) * 2014-11-05 2017-03-01 Lilly Co Eli Anticuerpos biespecíficos anti-tnf- / anti-il-23
KR20180054851A (ko) * 2015-10-30 2018-05-24 일라이 릴리 앤드 캄파니 항-cgrp/항-il-23 이중특이적 항체 및 그의 용도
TW201902926A (zh) 2017-05-03 2019-01-16 美商美國禮來大藥廠 抗cgrp／抗il-23雙特異性抗體及其用途
TWI744617B (zh) 2018-03-30 2021-11-01 美商美國禮來大藥廠 治療潰瘍性結腸炎之方法
TWI808397B (zh) 2018-09-11 2023-07-11 美商美國禮來大藥廠 治療牛皮癬之方法
MX2021012848A (es) 2019-04-22 2021-12-10 Lilly Co Eli Mirikizumab para su uso en un metodo de tratamiento de la enfermedad de crohn.
JP7551744B2 (ja) 2019-10-15 2024-09-17 イーライ リリー アンド カンパニー 組換え操作された、リパーゼ／エステラーゼ欠損哺乳動物細胞株
CN115135671A (zh) 2019-12-20 2022-09-30 新石生物制药有限公司 抗白介素-23 p19的抗体及其使用方法
CN112807428B (zh) * 2020-06-12 2024-08-27 江苏荃信生物医药股份有限公司 包含抗人白介素23单克隆抗体的药物组合物
WO2022041390A1 (zh) * 2020-08-28 2022-03-03 江苏荃信生物医药股份有限公司 包含高浓度抗人白介素23单克隆抗体的低粘度液体制剂及其制备方法
AR123477A1 (es) * 2020-09-10 2022-12-07 Lilly Co Eli Formulaciones de anticuerpos terapéuticos
WO2022251623A1 (en) 2021-05-28 2022-12-01 Eli Lilly And Company Anti-il-23p19 antibody regulation of genes involved in ulcerative colitis
CN113698480B (zh) * 2021-09-18 2022-07-01 东大生物技术(苏州)有限公司 一组il-23单克隆抗体及其医药用途
WO2023056417A1 (en) 2021-09-30 2023-04-06 Eli Lilly And Company Anti-il-23p19 antibody regulation of genes involved in bowel urgency in ulcerative colitis
WO2024077113A1 (en) * 2022-10-06 2024-04-11 Eli Lilly And Company Methods of treating fatigue in ulcerative colitis
WO2024178157A1 (en) 2023-02-22 2024-08-29 Eli Lilly And Company Regulation of genes in ulcerative colitis and the uses thereof
WO2024191771A1 (en) 2023-03-10 2024-09-19 Eli Lilly And Company Methods of treating ulcerative colitis

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6060284A (en) 1997-07-25 2000-05-09 Schering Corporation DNA encoding interleukin-B30
US7090847B1 (en) 1999-09-09 2006-08-15 Schering Corporation Mammalian cytokines; related reagents and methods
US7422743B2 (en) 2000-05-10 2008-09-09 Schering Corporation Mammalian receptor protein DCRS5;methods of treatment
ES2330220T3 (es) 2003-03-10 2009-12-07 Schering Corporation Usos de antagonistas de il-23; reactivos relacionados.
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
CA2613818C (en) * 2005-06-30 2013-08-27 Centocor, Inc. Anti-il-23 antibodies, compositions, methods and uses
CN101248088A (zh) * 2005-08-25 2008-08-20 伊莱利利公司 抗il-23抗体
PL1937721T3 (pl) * 2005-08-25 2010-12-31 Lilly Co Eli Przeciwciała anty-IL23
SG165322A1 (en) * 2005-08-31 2010-10-28 Schering Corp Engineered anti-il-23 antibodies
EA035459B1 (ru) * 2005-12-29 2020-06-19 Сентокор, Инк. Антитело против il-23p19
EP2426145B1 (en) * 2007-02-23 2017-01-18 Merck Sharp & Dohme Corp. Engineered anti-il-23p19 antibodies
PL2426144T3 (pl) * 2007-02-23 2019-05-31 Merck Sharp & Dohme Przeciwciała Anty-IL-23p19 wytworzone metodą inżynierii genetycznej
CN101646457B (zh) * 2007-03-20 2013-05-01 伊莱利利公司 抗硬骨素抗体
PE20090245A1 (es) * 2007-05-08 2009-03-17 Genentech Inc Anticuerpos anti-muc16 disenados con cisteina y conjugados de anticuerpos y farmacos
WO2009082624A2 (en) * 2007-12-10 2009-07-02 Zymogenetics, Inc. Antagonists of il-17a, il-17f, and il-23 and methods of using the same
WO2010142534A1 (en) * 2009-05-27 2010-12-16 Ablynx Nv Biparatopic protein constructs directed against il-23
JP6126532B2 (ja) * 2010-11-04 2017-05-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗ｉｌ−２３抗体
WO2012155019A1 (en) * 2011-05-12 2012-11-15 Genentech, Inc. Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature pepides

Also Published As

Publication number Publication date
JOP20140049B1 (ar) 2021-08-17
IL240731B (en) 2020-01-30
CY2023021I1 (el) 2024-02-16
AP2015008708A0 (en) 2015-09-30
KR20170103037A (ko) 2017-09-12
FR23C1036I1 (fr) 2023-12-08
US20150232552A1 (en) 2015-08-20
EA201591368A1 (ru) 2015-12-30
NZ711147A (en) 2021-03-26
IL272042B (en) 2021-07-29
JP2016510744A (ja) 2016-04-11
AU2014226094A1 (en) 2015-08-27
HUE051357T2 (hu) 2021-03-01
CA2901462C (en) 2017-07-25
JP6096938B2 (ja) 2017-03-15
TN2015000348A1 (en) 2017-01-03
CN105307681A (zh) 2016-02-03
BR112015019611B1 (pt) 2023-05-02
KR101775115B1 (ko) 2017-09-05
MA38382A1 (fr) 2017-11-30
PL2964258T3 (pl) 2021-02-08
US20140255422A1 (en) 2014-09-11
PT2964258T (pt) 2020-11-06
BR112015019611A2 (pt) 2017-08-22
EP3789037A1 (en) 2021-03-10
CL2015002388A1 (es) 2016-03-04
EA031524B1 (ru) 2019-01-31
SI2964258T1 (sl) 2020-10-30
HUS2300036I1 (hu) 2024-07-28
KR20150113202A (ko) 2015-10-07
NO2023037I1 (no) 2023-10-04
UA123198C2 (uk) 2021-03-03
HRP20201633T1 (hr) 2020-12-25
NL301247I1 (nl) 2023-10-11
CA2901462A1 (en) 2014-09-12
US9688753B2 (en) 2017-06-27
TW201520225A (zh) 2015-06-01
EP2964258A4 (en) 2016-10-12
EP4311558A2 (en) 2024-01-31
EP4311558A3 (en) 2024-04-10
LT2964258T (lt) 2020-10-12
HK1212252A1 (en) 2016-06-10
NL301247I2 (nl) 2023-11-01
AU2014226094B2 (en) 2016-06-23
PH12015501994A1 (en) 2016-01-11
EP2964258A1 (en) 2016-01-13
FR23C1036I2 (fr) 2024-10-04
FIC20230030I1 (fi) 2023-10-03
MX2015011959A (es) 2016-04-07
IL272042A (en) 2020-02-27
EP2964258B1 (en) 2020-09-02
TWI636063B (zh) 2018-09-21
ES2822662T3 (es) 2021-05-04
CY1123589T1 (el) 2022-03-24
RS60928B1 (sr) 2020-11-30
US20170275356A1 (en) 2017-09-28
AR094877A1 (es) 2015-09-02
SG11201507176VA (en) 2015-10-29
ZA201505285B (en) 2017-11-29
PE20151529A1 (es) 2015-10-28
MY171226A (en) 2019-10-03
US9023358B2 (en) 2015-05-05
WO2014137962A1 (en) 2014-09-12
MX370396B (es) 2019-12-11
IL240731A0 (en) 2015-10-29
CN105307681B (zh) 2018-06-26
DK2964258T3 (da) 2020-09-14

Similar Documents

Publication Publication Date Title
ECSP15038626A (es) A61k 30/395
CL2018001141A1 (es) Anticuerpo que neutraliza el virus respiratorio sincitial humano.
AR105600A1 (es) Anticuerpos contra la angiopoyetina implicada en metabolismo de los triglicéridos (anti-angptl8) y usos de los mismos
EA201790377A1 (ru) Антитела к глюкагону и их применения
EA201892790A1 (ru) Применение 2-замещенных индазолов для лечения и профилактики аутоиммунных заболеваний
MD4733C1 (ro) Anticorpi anti-TIGIT
PH12015500480A1 (en) Antibody formulations and uses thereof
CL2012000524A1 (es) Anticuerpo humanizado que se une a cdcp1 humana útil en el tratamiento del cáncer; composición farmacéutica; ácido nucleico, vector de expresión y célula huésped que lo comprende; y método para producir el anticuerpo.
MX2016006101A (es) Agente ligante de la il-17a y usos del mismo.
BR112014025649A2 (pt) anticorpos biespecíficos anti-baff-anti-il-17
CR20130108A (es) Anticuerpos contra la tweak humana y usos de los mismos
EA201890747A1 (ru) Способы лечения воспалительных заболеваний
EA201290360A1 (ru) Гуманизированные антитела против il-22ra человека
MX2015008877A (es) Conjugados de disulfuro mixto de compuestos de tienopiridina y sus usos.
NI201200144A (es) Anticuerpos humanizados de il - 25
PL423259A1 (pl) Koniugaty przeciwciało-ureaza dla celów terapeutycznych
EA201591514A1 (ru) Антитела к пан-хемокинам подсемейства elrcxc
MA45997A (fr) Méthodes de traitement de la maladie de crohn avec un anticorps anti-nkg2d
ECSP23070234A (es) Anti-cd30l antibodies and uses thereof
EA201691828A1 (ru) Прозрачное экструдированное туалетное мыло
MX2017013772A (es) Conjugados mezclados de disulfuro de compuestos de tienopiridina y usos de los mismos.
EA201790973A1 (ru) A-антагонист в низкой дозировке для лечения adhd и болезни паркинсона
BR112014030992A2 (pt) composições compreendendo calcogenetos e métodos relacionados
CO6680666A2 (es) Anticuerpos contra la tweak humana y usos de los mismos